Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants
about
Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents.Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.Developmental pharmacokinetic changes of Lamivudine in infants and childrenAntiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Developments in early diagnosis and therapy of HIV infection in newborns.Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome.Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations.Antiretroviral therapy during the neonatal period.British HIV Association guidelines for the management of HIV infection in pregnant women 2012
P2860
Q35065937-B82D8B1B-9F5A-4383-BD1A-299ACDD88FFFQ35171059-F29B0B64-FDA9-4DC2-9015-363F6D40D2B2Q36013430-DA1ED2E8-3419-45EE-98FD-4A588DB159A3Q37115759-C92E1185-B446-4BA3-9E52-5871A1E7FD2FQ37731863-30BFC3DE-F3AA-4D48-A651-57F0FB74BDC7Q37835819-F35A79B1-F20B-49FE-A4B8-09EBC8E96DBEQ38325427-EBF1BEDB-CA32-4FE4-AEA9-8B66463BE66EQ38648601-4BBC239D-4729-4BA9-9EC8-1D45CFE0E509Q38771392-5BB81FA2-178E-4601-A6D8-A585008E05A0Q38868724-3E50D347-E036-49F0-B86C-A75C8396F696Q40867191-484392BF-3FF7-4DB9-8389-EE0812F888A5Q41881433-44FB648D-9690-4146-91E3-49B45CD1C0F0Q42661142-C6A0FF42-57E0-4047-B5FA-7315C17DA455Q45932455-C9B89FDB-B2CA-439A-BBB4-1AA9FA0F387AQ53801515-2E25133E-C944-40F4-92AD-A26E42E5D590Q57076282-7C38BF0A-77DD-4571-819F-0F2293E4C5EA
P2860
Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Population pharmacokinetics of ...... -exposed and -infected infants
@ast
Population pharmacokinetics of ...... -exposed and -infected infants
@en
type
label
Population pharmacokinetics of ...... -exposed and -infected infants
@ast
Population pharmacokinetics of ...... -exposed and -infected infants
@en
prefLabel
Population pharmacokinetics of ...... -exposed and -infected infants
@ast
Population pharmacokinetics of ...... -exposed and -infected infants
@en
P2093
P2860
P356
P1476
Population pharmacokinetics of ...... -exposed and -infected infants
@en
P2093
Adriana H Tremoulet
Carmen Zorrilla
Diane Holland
Diane Wara
Edmund V Capparelli
Edward P Acosta
Katherine Luzuriaga
Mark Mirochnick
Parul Patel
Pediatric AIDS Clinical Trials Group
P2860
P304
P356
10.1128/AAC.00332-07
P407
P577
2007-09-24T00:00:00Z